Radiotherapy quality assurance in the TROG 12.01 randomised trial and its impact on loco-regional failure

- Corry, June, Moore, Alisha, Mcdowell, Lachlan, Wilkinson, Dean, Tiong, Albert, Rischin, Danny, Kenny, Liz, Wratten, Chris, Fua, Tsien, Lin, Charles, Porceddu, Sandro, Liu, Chen, Ruemelin, Michael, Sharkey, Amy

Stereotactic ablative body radiotherapy for primary kidney cancer (TROG 15.03 FASTRACK II): a non-randomised phase 2 trial

- Siva, Shankar, Bressel, Mathias, Lin, Charles, Raman, Avi, Hardcastle, Nicholas, Hofman, Michael S., De Abreu Lourenco, Richard, Shaw, Mark, Mancuso, Pascal, Moon, Daniel, Wong, Lih-Ming, Lawrentschuk, Nathan, Sidhom, Mark, Wood, S, Brook, NR, Kron, T, Martin, Jarad, Pryor, D, FASTRACK II Investigator Group,, Sridharan, Swetha, Vanneste, Ben G. L., Davey, Ryan, Montgomery, Rebecca, Ruben, Jeremy, Foroudi, Farshad, Higgs, Braden

Randomized Trial of Radiation Therapy With Weekly Cisplatin or Cetuximab in Low-Risk HPV-Associated Oropharyngeal Cancer (TROG 12.01) – A Trans-Tasman Radiation Oncology Group Study

- Rischin, Danny, King, Madeleine, Fua, Tsien, Lin, Charles, Liu, Chen, Hughes, Brett G. M., McGrath, Margaret, McDowell, Lachlan, Corry, June, Kenny, Lizabeth, Porceddu, Sandro, Wratten, Christopher, Macann, Andrew, Jackson, James E., Bressel, Mathias, Herschtal, Alan, Fisher, Richard